GT Metabolic Solutions, Inc., the self-described world leader in magnetic surgery, announced today that the U.S. Food and Drug Administration (FDA) has cleared a larger 50mm MagDI System magnet to complement the system's existing 40mm magnet. This expansion enables surgeons to accommodate a broader range of patients requiring magnet-assisted surgery for duodenal-ileal anastomosis.
The MagDI System is currently the only FDA-cleared and commercially available product for magnetic compression anastomosis. The technology is designed to be self-aligning, incisionless, sutureless, and staple-free, facilitating anastomosis without leaving behind foreign material in the patient's body.
Clinical Experience and Surgeon Feedback
Dr. Phil Gachassin, Medical Director of Metabolic and Bariatric Surgery at Ochsner Lafayette General Medical Center, shared his positive early experience with the system: "The results have been promising, and I'm especially impressed with how my patients are responding to the magnetic compression anastomosis technique." Gachassin and his team were among the first in Louisiana to implement the MagDI System with the 40mm magnet.
The clinical evidence supporting the efficacy of this approach continues to grow. According to the company, there are no reported leaks or bleeds attributed to this sutureless, staple-free technique to date.
Enhanced Surgical Flexibility
With the addition of the 50mm magnet option, the MagDI System now offers surgeons greater flexibility to tailor procedures to individual patient needs. The larger magnet will be used in the same procedure as the 40mm magnet to facilitate a seamless, non-invasive approach to anastomosis.
"This expansion reinforces our commitment to pushing the boundaries of minimally invasive, magnetic surgery and providing surgeons with more advanced tools to improve patient outcomes," said Thierry Thaure, Chief Executive Officer and co-founder of GT Metabolic Solutions.
Innovation in Bariatric Surgery
The MagDI System represents a significant innovation in bariatric surgical techniques. The magnetic compression approach creates anastomosis while potentially minimizing complications such as leaks and bleeds in challenging applications.
Dr. Michel Gagner, Chief Medical Officer and co-founder of GT Metabolic Solutions, who created the system, emphasized the significance of the expanded offering: "The clinical success we've seen so far reinforces the role of magnetic compression for anastomosis in bariatric surgery today, and bringing the option of a larger 50mm magnet allows us to broaden the impact of the MagDI System."
Market Expansion Plans
As demand for less invasive, more efficient surgical techniques grows, GT Metabolic is committed to accelerating the U.S. market release of the MagDI System in collaboration with leading surgeons and hospital centers.
"We are thrilled by the growing interest in the MagDI System and what it means for the future of bariatric surgery," said Ronald Galovich, Vice President Sales & Marketing at GT Metabolic. "We look forward to expanding opportunities for surgeons who are eager for solutions that enhance anastomosis procedural efficiency while improving patient outcomes. The approval of the 50mm magnet is another step in meeting that demand."
About the Technology
GT Metabolic Solutions' magnetic compression anastomosis technology, also called delayed anastomosis technology (DAT), uses magnets to achieve anastomosis through an incisionless, sutureless, staple-free technique that leaves no foreign material to impede the natural tissue healing process.
The company states that their solution "democratizes the surgical approach to anastomosis," can be used in procedure staging, and is completely reversible. This approach may represent a significant advancement in bariatric, metabolic, and digestive health surgical procedures.
